(CNBC) Gilead Sciences said that a draft document showing disappointing results from a closely watched clinical trial of the company’s treatment for the coronavirus contained “inappropriate characterizations” and that the study’s findings were “inconclusive.”
Shares of the biotech firm fell 4% in intraday trading Thursday after the Financial Times reported that antiviral drug remdesivir did not improve Covid-19 patients’ conditions or reduce the virus’ presence in the bloodstream in a clinical trial in China. The report, citing a draft document that was accidentally published by the World Health Organization and has since been removed, also said the drug showed significant side effects, and some patients were taken off of it.